Recently stock market analysts have updated their consensus ratings on shares of Akers Biosciences Inc (AKER). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

01/20/2015 – Akers Biosciences Inc had its “” rating reiterated by analysts at finnCap. They now have a USD 310 price target on the stock.

11/21/2014 – Akers Biosciences Inc had its “hold” rating reiterated by analysts at S&P Capital IQ. They now have a USD 34 price target on the stock.

07/17/2014 – Akers Biosciences Inc had its “buy” rating reiterated by analysts at Daniel Stewart. They now have a USD 752 price target on the stock.

06/09/2014 – Aegis Capital began new coverage on Akers Biosciences Inc giving the company a “buy” rating. They now have a USD 11 price target on the stock.

Akers Biosciences Inc has a 50 day moving average of 1.66 and a 200 day moving average of 1.75. The stock’s market capitalization is 8.02M, it has a 52-week low of 1.08 and a 52-week high of 5.14.

The share price of the company (AKER) was up +0.00% during the last trading session, with a high of 0.00 and the volume of Akers Biosciences Inc shares traded was 105.

View other investors thoughts on Akers Biosciences Inc on our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.